Results 181 to 190 of about 857,044 (346)

deltaHED predicts survival and immune evasion in PD-1 blockade therapy: A multi-cohort study across three cancer types. [PDF]

Clin Transl Med
Xu J, Wei X, Yao J, Mahajan UM, Kahlert UD, Shi R, Zhang K, Alnatsha A, Qian Z, Han F, Wang F.   +10 more
europepmc   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model. [PDF]

Cancer Immunol Immunother
Saito M, Kunieda K, Ishii T, Koshiba S, Ohashi R, Kanda Y, Yamada T.   +6 more
europepmc   +1 more source

Rydberg-interaction-based quantum gates free from blockade error [PDF]

, 2016
Xiaofeng Shi
openalex  

Blockade of associative spine enlargement impairs awake cortical function [PDF]

Siqi Zhou, Takeshi Sawada, Tomoki Arima, Sadam Khan Panezai, Masanari Ohtsuka, Hitoshi Okazaki, Shunki Takaramoto, Shin-Ichiro Terada, Masashi Kondo, Takayuki Hashimoto, Kenichi Ohki, M Matsuzaki, Sho Yagishita, Haruo Kasai   +13 more
openalex   +1 more source

Abnormalities of Left Ventricular Contraction Induced by Beta Adrenergic Blockade [PDF]

, 1971
Richard H. Helfant, Michael V. Herman, Richard Gorlin   +2 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Very Late Recurrence of Clear Cell Renal Cell Carcinoma With Pancreatic and Hepatic Metastases Showing Durable Response to Dual Checkpoint Blockade. [PDF]

Clin Case Rep
Ito F, Kobayashi K, Hayashi G, Kamijo S, Fujita T.   +4 more
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study. [PDF]

MedComm (2020)
Huang J, Wang H, Tong Y, Hong J, Zhu Y, Ren W, Yu J, Shi H, Gao W, Zhu S, Wu J, Huang O, Li J, He J, Chen W, Li Y, Shen K, Chen X.   +17 more
europepmc   +1 more source